Search - tctmd.com

Displaying 21 - 40 of 41

Sort: Relevancy | Date

News Daily News

ATTRibute-CM Top-Line Results Favorable for Acoramidis

L.A. McKeown

July 17, 2023

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

Shelley Wood

May 23, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

Shelley Wood

August 28, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2020

Shelley Wood

January 31, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Shelley Wood

December 23, 2019

News Daily News

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

L.A. McKeown

July 02, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Industry News

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

May 06, 2019

News Features

Year in Review: Physicians Pick the Biggest News of 2018

TCTMD News Team

December 29, 2018

News Features

Top News in Structural Heart Disease: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Shelley Wood

September 14, 2018

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Advertisement

ATTRibute-CM Top-Line Results Favorable for Acoramidis

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

TCTMD’s Top 10 Most Popular Stories for September 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

TCTMD’s Top 10 Most Popular Stories for January 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

Carpal Tunnel Linked to Higher Rates of Amyloidosis and Heart Failure

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis

Year in Review: Physicians Pick the Biggest News of 2018

Top News in Structural Heart Disease: 2018

Top News in Heart Failure: 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content